within Pharmacolibrary.Drugs.ATC.N;

model N05AN01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.95,
    Cl             = 0.0003333333333333333,
    adminDuration  = 600,
    adminMass      = 300 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0007,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0007,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N05AN01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Lithium is a mood stabilizer primarily used in the treatment and prophylaxis of bipolar disorder and, to a lesser extent, depression. It is an approved drug with established efficacy for the prevention of manic and depressive episodes in bipolar disorder. Lithium is also sometimes used off-label for other psychiatric conditions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adults after oral administration of lithium carbonate.</p><h4>References</h4><ol><li><p>Wen, J, et al., &amp; Tan, J (2019). A Review for Lithium: Pharmacokinetics, Drug Design, and Toxicity. <i>CNS &amp; neurological disorders drug targets</i> 18(10) 769–778. DOI:<a href=&quot;https://doi.org/10.2174/1871527318666191114095249&quot;>10.2174/1871527318666191114095249</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31724518/&quot;>https://pubmed.ncbi.nlm.nih.gov/31724518</a></p></li><li><p>Altamura, AC, et al., &amp; Percudani, M (1994). Clinical pharmacokinetics of fluoxetine. <i>Clinical pharmacokinetics</i> 26(3) 201–214. DOI:<a href=&quot;https://doi.org/10.2165/00003088-199426030-00004&quot;>10.2165/00003088-199426030-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8194283/&quot;>https://pubmed.ncbi.nlm.nih.gov/8194283</a></p></li><li><p>DeVane, CL, &amp; Nemeroff, CB (2001). Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. <i>Clinical pharmacokinetics</i> 40(7) 509–522. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200140070-00003&quot;>10.2165/00003088-200140070-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11510628/&quot;>https://pubmed.ncbi.nlm.nih.gov/11510628</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N05AN01;
